Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

sun pharmaceutical industries, inc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination

Kanada - engleski - Health Canada

glaxosmithkline inc - nabumetone - tablet - 750mg - nabumetone 750mg - other nonsteroidal antiimflammatory agents

Kanada - engleski - Health Canada

pro doc limitee - nabumetone - tablet - 500mg - nabumetone 500mg - other nonsteroidal antiimflammatory agents

Kanada - engleski - Health Canada

teva canada limited - nabumetone - tablet - 500mg - nabumetone 500mg - other nonsteroidal antiimflammatory agents

Kanada - engleski - Health Canada

teva canada limited - nabumetone - tablet - 750mg - nabumetone 750mg - other nonsteroidal antiimflammatory agents

Kanada - engleski - Health Canada

mylan pharmaceuticals ulc - nabumetone - tablet - 500mg - nabumetone 500mg - other nonsteroidal antiimflammatory agents

Kanada - engleski - Health Canada

sanis health inc - nabumetone - tablet - 500mg - nabumetone 500mg - other nonsteroidal antiimflammatory agents

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

eon labs, inc. - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - sulfadiazine tablets, usp are indicated in the following conditions: chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, staphylococcus aureus , proteus mirabilis and p. vulgaris . sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. malaria due to chloroquine-resistant strains of plasmodium falciparum , when used as adjunctive therapy. prophylaxis of meningococcal meningitis when sulfonamide-sensitive group a strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

epic pharma, llc - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - sulfadiazine tablets, usp are indicated in the following conditions: chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, staphylococcus aureus, proteus mirabilis and p. vulgaris . sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. malaria due to chloroquine-resistant strains of plasmodium falciparum , when used as adjunctive therapy. prophylaxis of meningococcal meningitis when sulfonamide-sensitive group a strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups). meningococcal meningitis, when the organism has been demonstrated to be susceptible. acute otitis media due to haemophilus influenzae, when used concomitantly with adequate doses of penicilin. prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. h. influenzae meningitis, as adjunctive therapy with parental streptomycin. important notes in vitro sulfonamide susceptibility tests are not always reliable. the test must be carefully coordinated with bacteriologic and clinical response. when the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. wide variation in blood levels may result with identical doses. blood levels should be measured in patients receiving sulfonamides for serious infections. free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections. twenty mg per 100 ml should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. sulfadiazine is contraindicated in the following circumstances: hypersensitivity to sulfonamides. in infants less than 2 months of age (except as adjunctive therapy with pyrimethamine in the treatment of congenital toxoplasmosis). in pregnancy at term and during the nursing period, because sulfonamides cross the placenta and are excreted in breast milk and may cause kernicterus.